SATVI - after 10 years closing in on a new and better vaccine to prevent tuberculosis

S Afr Med J. 2012 Mar 2;102(6):438-41. doi: 10.7196/samj.5773.

Abstract

The vision of the South African Tuberculosis Vaccine Initiative (SATVI) (www.satvi.uct.ac.za) is 'A World Without TB' and our mission is 'Innovative and high-quality TB vaccine research in Africa, to impact the global epidemic'. Over the last 10 years, our focus has been twofold: first, clinical trials of BCG and of new candidate vaccines, and second, complementary research that addresses critical questions in TB vaccine development. SATVI is now widely regarded as the leading TB vaccine clinical research site in the world.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • BCG Vaccine
  • Clinical Trials as Topic
  • Cooperative Behavior
  • Humans
  • Infant
  • Mycobacterium tuberculosis / immunology
  • Schools, Medical
  • South Africa
  • Tuberculosis Vaccines*
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / prevention & control*
  • Universities*

Substances

  • BCG Vaccine
  • Tuberculosis Vaccines